Abstract: The invention provides pharmaceutical compositions and methods of use thereof for preventing or ameliorating disorders of the nervous system. More specifically, the invention provides pharmaceutical compositions, including phosphopeptides that when administered disrupt the physical interaction of TrkB with its signaling effector, phospholipase C?1 (PLC?1). The invention further provides method of treatment comprising administering phosphopeptides that uncouple TrkB from PLC?1 in order to prevent and/or ameliorate nervous system disorders such as epilepsy, anxiety, and seizures.

Abstract: The invention provides pharmaceutical compositions and methods of use thereof for preventing or ameliorating disorders of the nervous system. More specifically, the invention provides pharmaceutical compositions, including phosphopeptides that when administered disrupt the physical interaction of TrkB with its signaling effector, phospholipase C?1 (PLC?1). The invention further provides method of treatment comprising administering phosphopeptides that uncouple TrkB from PLC?1 in order to prevent and/or ameliorate nervous system disorders such as epilepsy, anxiety, and seizures.

Abstract: The invention provides pharmaceutical compositions and methods of use thereof for preventing or ameliorating disorders of the nervous system. More specifically, the invention provides pharmaceutical compositions, including phosphopeptides that when administered disrupt the physical interaction of TrkB with its signaling effector, phospholipase C?1 (PLC?1). The invention further provides method of treatment comprising administering phosphopeptides that uncouple TrkB from PLC?1 in order to prevent and/or ameliorate nervous system disorders such as epilepsy, anxiety, and seizures.

Abstract: The present disclosure relates to methods of preventing or treating epilepsy comprising administering a receptor tyrosine kinase B (TrkB) inhibitor. In particular, the present disclosure relates to methods of treating a subject susceptible to the development of epilepsy, methods of inducing remission of epilepsy in a subject, and methods of transforming medically refractory epilepsy in a subject to medically responsive epilepsy comprising administering a therapeutically effective amount of a TrkB inhibitor or a phospholipase C?1 (PLC?1) inhibitor.

Abstract: The invention provides pharmaceutical compositions and methods of use thereof for preventing or ameliorating disorders of the nervous system. More specifically, the invention provides pharmaceutical compositions, including phosphopeptides that when administered disrupt the physical interaction of TrkB with its signaling effector, phospholipase C?1 (PLC?1). The invention further provides method of treatment comprising administering phosphopeptides that uncouple TrkB from PLC?1 in order to prevent and/or ameliorate nervous system disorders such as epilepsy, anxiety, and seizures.

Abstract: The invention provides pharmaceutical compositions and methods of use thereof for preventing or ameliorating disorders of the nervous system. More specifically, the invention provides pharmaceutical compositions, including phosphopeptides that when administered disrupt the physical interaction of TrkB with its signaling effector, phospholipase C?1 (PLC?1). The invention further provides method of treatment comprising administering phosphopeptides that uncouple TrkB from PLC?1 in order to prevent and/or ameliorate nervous system disorders such as epilepsy, anxiety, and seizures.

Abstract: The invention provides pharmaceutical compositions and methods of use thereof for preventing or ameliorating disorders of the nervous system. More specifically, the invention provides pharmaceutical compositions, including phosphopeptides, that when administered disrupt TrkB-mediated activation of PLC?1 phosphorylation. The invention further provides method of treatment comprising administering inhibitors of TrkB-mediated activation of PLC?1 phosphorylation alone or in combination with other pharmaceutical compositions to prevent or ameliorate nervous system disorders such as epilepsy, stroke, anxiety, migraine, and pain.

Abstract: The invention provides pharmaceutical compositions and methods of use thereof for preventing or ameliorating disorders of the nervous system. More specifically, the invention provides pharmaceutical compositions, including phosphopeptides, that when administered disrupt TrkB-mediated activation of PLC?1 phosphorylation. The invention further provides method of treatment comprising administering inhibitors of TrkB-mediated activation of PLC?1 phosphorylation alone or in combination with other pharmaceutical compositions to prevent or ameliorate nervous system disorders such as epilepsy, stroke, anxiety, migraine, and pain.